FXYD3 has been reported to be highly expressed in diverse cancer tissues and its aberrant up‐regulation contributes to the development of breast cancer by activating PI3K‐AKT signalling.23, 24 Aberrantly activated PI3K‐AKT is frequently found in diverse cancers and is correlated with a worse prognosis and outcome.25, 26 Constituted activation of PI3K‐AKT signalling may be attributed to the mutation occurring in PI3K or AKT, mutation or amplification of RTKs, or overexpression of other upstream genes.23, 27, 28 PI3K/Akt pathway could further induce multidrug resistance in HCC.29 This evidence concerns the gene FXYD3 and breast carcinoma.